NASDAQ:AGEN - Agenus Stock Price, Forecast & News

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Agenus Inc (NASDAQ:AGEN) released its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.05. The biotechnology company had revenue of $19.94 million for the quarter, compared to analysts' expectations of $15.60 million. View Agenus' Earnings History.

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Agenus.

1 equities research analysts have issued 1-year price targets for Agenus' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 124.7% from the stock's current price. View Analyst Price Targets for Agenus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.

Press coverage about AGEN stock has trended extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agenus earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Agenus.

Agenus saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 11,720,000 shares, an increase of 5.0% from the January 30th total of 11,160,000 shares. Based on an average trading volume of 1,340,000 shares, the short-interest ratio is presently 8.7 days. Approximately 11.1% of the company's shares are short sold. View Agenus' Current Options Chain.

Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), Merrimack Pharmaceuticals (MACK), REDHILL BIOPHAR/S (RDHL), Opko Health (OPK), Gilead Sciences (GILD), Energy Transfer LP Unit (ET), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Agenus' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (2.86%), Oracle Investment Management Inc. (2.02%), Geode Capital Management LLC (1.10%), Panagora Asset Management Inc. (0.69%), Charles Schwab Investment Management Inc. (0.52%) and Bank of New York Mellon Corp (0.34%). View Institutional Ownership Trends for Agenus.

AGEN stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Chicago Equity Partners LLC, Bank of America Corp DE, Charles Schwab Investment Management Inc., Strs Ohio, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank and Bank of New York Mellon Corp. View Insider Buying and Selling for Agenus.

AGEN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Oracle Investment Management Inc., Captrust Financial Advisors, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, Hussman Strategic Advisors Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for Agenus.

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGEN stock can currently be purchased for approximately $2.67.

Agenus has a market capitalization of $366.75 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus.

The official website for Agenus is http://agenusbio.com/.

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]